Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

French (CAC) Healthcare Sector Analysis

UpdatedFeb 27, 2026
DataAggregated Company Financials
Companies55
  • 7D2.2%
  • 3M-11.3%
  • 1Y-11.7%
  • YTD-4.6%

In the last week, the Healthcare industry is up 2.2%, with EssilorLuxottica Société anonyme up 2.7%. During this same period, the ABIVAX Société Anonyme underperformed, falling 6.5%. However, the industry is down 12% over the past year. Earnings are forecast to grow by 17% annually.

Sector Valuation and Performance

Has the French Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 27 Feb 2026€285.7b€117.1b€7.6b21.8x37.4x2.4x
Sun, 25 Jan 2026€297.7b€114.7b€9.2b22.8x32.5x2.6x
Tue, 23 Dec 2025€301.7b€114.8b€9.2b21x32.7x2.6x
Thu, 20 Nov 2025€311.2b€114.8b€9.5b21.9x32.7x2.7x
Sat, 18 Oct 2025€316.6b€114.8b€9.5b21x33.4x2.8x
Mon, 15 Sep 2025€285.2b€114.6b€9.3b20.5x30.8x2.5x
Wed, 13 Aug 2025€283.2b€114.3b€9.3b20.3x30.4x2.5x
Fri, 11 Jul 2025€285.9b€112.6b€9.0b23x31.7x2.5x
Sun, 08 Jun 2025€287.6b€112.6b€9.0b23.9x32x2.6x
Tue, 06 May 2025€301.1b€112.6b€8.9b23.2x33.8x2.7x
Thu, 03 Apr 2025€307.2b€111.3b€10.1b21x30.4x2.8x
Sat, 01 Mar 2025€327.1b€110.9b€9.9b24.6x33.1x3x
Mon, 27 Jan 2025€305.4b€113.9b€9.1b19.9x33.6x2.7x
Wed, 25 Dec 2024€280.6b€113.9b€9.1b21.7x31x2.5x
Fri, 22 Nov 2024€276.9b€113.9b€9.1b20.6x30.6x2.4x
Sun, 20 Oct 2024€291.3b€112.5b€8.8b23.2x33.1x2.6x
Tue, 17 Sep 2024€287.8b€112.1b€8.6b21.2x33.6x2.6x
Thu, 15 Aug 2024€279.2b€111.8b€8.6b23x32.5x2.5x
Sat, 13 Jul 2024€271.2b€110.0b€9.0b23.8x30x2.5x
Mon, 10 Jun 2024€274.5b€110.0b€9.0b25x30.4x2.5x
Wed, 08 May 2024€272.1b€104.9b€7.6b24x35.9x2.6x
Fri, 05 Apr 2024€273.3b€104.7b€8.6b20.5x31.9x2.6x
Sun, 03 Mar 2024€266.5b€104.5b€8.6b21.2x30.8x2.5x
Tue, 30 Jan 2024€265.6b€104.0b€12.7b21.4x20.9x2.6x
Thu, 28 Dec 2023€261.1b€104.0b€12.7b21.5x20.6x2.5x
Sat, 25 Nov 2023€250.7b€104.0b€12.7b20.7x19.7x2.4x
Mon, 23 Oct 2023€255.1b€104.6b€12.3b19.6x20.7x2.4x
Wed, 20 Sep 2023€274.5b€104.8b€12.4b21.6x22.2x2.6x
Fri, 18 Aug 2023€271.0b€104.5b€12.5b21.9x21.7x2.6x
Sun, 16 Jul 2023€263.5b€103.8b€12.4b19.6x21.2x2.5x
Tue, 13 Jun 2023€264.3b€103.8b€12.4b20.2x21.3x2.5x
Thu, 11 May 2023€275.9b€108.3b€12.1b20.6x22.8x2.5x
Sat, 08 Apr 2023€276.0b€107.8b€12.4b20.1x22.3x2.6x
Mon, 06 Mar 2023€260.8b€107.7b€12.8b19.9x20.4x2.4x
Price to Earnings Ratio

20.4x


Total Market Cap: €260.8bTotal Earnings: €12.8bTotal Revenue: €107.7bTotal Market Cap vs Earnings and Revenue0%0%0%
French Healthcare Sector Price to Earnings3Y Average 28.6x202420252026
Current Industry PE
  • Investors are optimistic on the French Healthcare industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 37.4x which is higher than its 3-year average PE of 28.6x.
  • The industry is trading close to its 3-year average PS ratio of 2.6x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have declined 16% per year over the last three years.
  • Meanwhile revenues for these companies have grown 2.8% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the French Healthcare sector?

FR Market2.31%
Healthcare2.17%
Healthcare Services5.61%
Healthtech2.88%
Medical Equipment2.64%
Life Sciences2.21%
Pharma2.13%
Biotech-3.65%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 43.0x.
    • Analysts are expecting annual earnings growth of 13.6%, which is higher than its past year's earnings decline of 5.0% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 58% over the next 5 years.
  • This is better than its past earnings decline of 22% per year.
  • In contrast, the Medical Equipment industry is expected to see its earnings grow by 14% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SAN Sanofi€82.203.3%
+€3.2b		-21.2%PE20.1x
IPN Ipsen€165.104.7%
+€607.5m		48.5%PE30.6x
BIM bioMérieux€100.005.0%
+€560.8m		-13.4%PE31.2x
NANO Nanobiotix€25.8018.3%
+€193.7m		644.8%PS123x
EMEIS emeis Société anonyme€15.387.5%
+€172.6m		40.3%PS0.4x

Latest News

BIM
€100.00
bioMérieux
7D
5.0%
1Y
-13.4%
SAN
€82.20
Sanofi
7D
3.3%
1Y
-21.2%
IPN
€165.10
Ipsen
7D
4.7%
1Y
48.5%
MEDCL
€23.04
MedinCell
7D
-3.5%
1Y
62.7%

MEDCL: 2026 Revenue Outlook And New Schizophrenia Drug Will Support Upside

Analysts have kept their price target for MedinCell steady at €35.26, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E in their latest update. What's in the News Teva Pharmaceuticals and MedinCell announced that the U.S. FDA has accepted the New Drug Application for TEV-'749, an olanzapine extended-release injectable suspension for adult schizophrenia treatment, using MedinCell’s SteadyTeq copolymer technology for controlled sustained drug release (Key Developments).
EMEIS
€15.38
emeis Société anonyme
7D
7.5%
1Y
40.3%
ABVX
€102.60
ABIVAX Société Anonyme
7D
-8.7%
1Y
1,378.4%
ERF
€68.16
Eurofins Scientific
7D
0.9%
1Y
41.1%

ERF: Updated Earnings Assumptions And Testing Expansion Will Shape Future Returns

Analysts have lifted their fair value estimate for Eurofins Scientific from about €66.34 to €71.71. This reflects updated assumptions on discount rates, revenue growth, profit margins and future P/E after recent price target increases, such as the €10.20 raise cited in Street research.
IVA
€5.49
Inventiva
7D
-2.3%
1Y
90.0%

IVA: 2026 MASH Phase 3 Readout Will Support Bullish Repricing View

Analysts have raised their Inventiva fair value estimate from €7.85 to approximately €8.98, citing recent Buy and Outperform initiations that underscore confidence in lanifibranor's MASH potential and a modest increase in the assumed future P/E multiple. Analyst Commentary Recent research coverage paints a generally constructive picture for Inventiva, with several firms starting or updating views that focus on lanifibranor's potential in MASH and re-rating the shares using higher P/E assumptions and price targets.
CLARI
€4.07
Clariane
7D
5.2%
1Y
10.6%

CLARI: Stable Assumptions And Lower P/E Multiple Will Support Bullish Momentum

Analysts have trimmed their 12 month price target for Clariane to €4.49. This reflects slightly adjusted assumptions on revenue growth, profit margins and future P/E expectations, while keeping the overall valuation framework unchanged.
EL
€225.20
EssilorLuxottica Société anonyme
7D
-5.5%
1Y
-21.5%

EL: Smart Eyewear Capacity Plans Will Test Premium Multiple Resilience

EssilorLuxottica Société anonyme's updated analyst price target has shifted from about €244.72 to €218.59, as analysts factor in slightly lower fair value assumptions and more conservative estimates for growth, margins and future P/E. This is reflected in a series of recent target trims from major banks alongside at least one rating upgrade.
NANO
€25.80
Nanobiotix
7D
18.3%
1Y
644.8%

New Forecasts: Here's What Analysts Think The Future Holds For Nanobiotix S.A. (EPA:NANO)

Jan 31
New Forecasts: Here's What Analysts Think The Future Holds For Nanobiotix S.A. (EPA:NANO)
VETO
€84.70
Vetoquinol
7D
-2.3%
1Y
16.8%
GNFT
€8.99
Genfit
7D
14.0%
1Y
157.8%
DBV
€3.59
DBV Technologies
7D
-1.5%
1Y
381.9%
BOI
€27.40
Boiron
7D
-1.8%
1Y
9.6%

Is Boiron (EPA:BOI) Using Too Much Debt?

Dec 05
Is Boiron (EPA:BOI) Using Too Much Debt?
ALCGM
€10.70
Cegedim
7D
-10.1%
1Y
-20.1%